GRAIL
Gordon Cann is an accomplished Principal Scientist at GRAIL, a position held since March 2016. Prior to joining GRAIL, Gordon Cann developed expertise as a Scientist II at Illumina from 2009 to March 2016. With extensive experience in genomic technologies and research, Gordon Cann contributes significantly to advancements in the field.
GRAIL
27 followers
GRAIL aims to develop a blood test to detect cancer early before symptoms appear offering higher survival rates compared to late-stage diagnosis.